Related Experiment Videos

Comparison of four pancreatic extracts in cystic fibrosis

Insights

Creon and Pancrease significantly reduced gastrointestinal symptoms and improved fat absorption in children with cystic fibrosis compared to Pancrex V Forte and Pancreatin Merck. These pancreatic enzyme therapies enable high-energy diets without restrictions.

Area of Science:

  • Gastroenterology
  • Pediatrics
  • Pharmacology

Background:

  • Cystic fibrosis (CF) often leads to pancreatic insufficiency.
  • Pancreatic enzyme replacement therapy (PERT) is crucial for managing CF-related malabsorption.
  • Evaluating the efficacy of different PERT formulations is essential for optimizing patient care.

Purpose of the Study:

  • To compare the efficacy of four pancreatin products in children with cystic fibrosis.
  • To assess gastrointestinal symptom relief and fat absorption.
  • To determine the impact on fecal nitrogen content.

Main Methods:

  • Randomized crossover trial involving children with cystic fibrosis.
  • Comparison of Pancrease, Creon, Pancrex V Forte, and Pancreatin Merck.
  • Evaluation of gastrointestinal symptoms, fat absorption, and fecal nitrogen levels.

Main Results:

  • Creon and Pancrease showed fewer gastrointestinal symptoms than Pancrex V Forte and Pancreatin Merck.
  • Pancrease significantly improved fat absorption compared to Pancrex V Forte and Pancreatin Merck.
  • Creon demonstrated superior fat absorption to Pancrex V Forte; no significant differences were found between Pancrease and Creon.

Conclusions:

  • Creon and Pancrease are effective pancreatic enzyme supplements for children with cystic fibrosis.
  • These products facilitate improved nutrient absorption and symptom management.
  • Patients can adhere to high-energy diets without dietary restrictions when using Creon or Pancrease.

Related Concept Videos